



Universiteit
Leiden
The Netherlands

Body composition, nutritional status and clinical outcomes in end-stage liver disease

Bot, D.

Citation

Bot, D. (2025, October 29). *Body composition, nutritional status and clinical outcomes in end-stage liver disease*. Retrieved from <https://hdl.handle.net/1887/4281117>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4281117>

Note: To cite this publication please use the final published version (if applicable).

(9



Chapter 9

Semaglutide for the treatment of post transplantation diabetes mellitus in patients following liver transplantation is safe and effective

Bot D, van Hoek B, Tushuizen ME.

**PUBLISHED IN
Annals of Hepatology, 2025**

Clinical letter

Dear Editor,

Post-Transplant Diabetes Mellitus (PTDM) is a frequent consequence of solid organ transplantation with an incidence of over 30%. (1) Similar to the findings in non-transplant settings, PTDM has been shown to be associated with an increased risk of cardiovascular disease and infectious complications. (1) With PTDM reduced patient survival and accelerated graft loss have been reported. Risk factors for PTDM include many of the immunosuppressive medications themselves as well as the well-known risk factors for type 2 diabetes mellitus (T2DM), including obesity, the metabolic syndrome and Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD)/Metabolic-dysfunction Associated Steatohepatitis (MASH). Treatment options for management of PTDM are limited with regards to the availability of strong clinical evidence.

Semaglutide is a once-weekly GLP-1RA injection and approved for treatment of adults with T2DM and is known for its high potency in reducing HbA1c, weight and blood pressure. The more frequent adverse events associated with the use of GLP-1RA were gastrointestinal reactions, such as nausea, vomiting, and diarrhea. Most events are mild to moderate in severity and leads in less than 5% of patients to treatment discontinuation. Contraindications for GLP-1RA treatment are history of chronic or idiopathic acute pancreatitis, personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, impaired renal function (estimated glomerular filtration rate [eGFR] <30 mL/min per 1.73 m²), and heart failure (New York Heart Association class IV).

We present here the data of 10 patients with PTDM following liver transplantation, without any contraindications for the use of GLP-1RA, treated with semaglutide 0.5 mg once weekly. The primary etiology following liver transplantation was MASLD/MASH in all patients, with 7 patients suffering from hepatocellular carcinoma. Mean time between liver transplantation and semaglutide treatment was 5 ± 1.3 years. Patients in this case report received semaglutide as part of usual care and not in trial settings. Therefore, ethical approval was waived by the local Ethics Committee of the LUMC. The case report adhered to the latest version of the declarations of Helsinki.

In 10 patients (mean $\pm$ SEM, age 54 ± 5 years), 6 months treatment with semaglutide resulted in a significant decrease of median HbA1c from 66.1 (32.2-20.2) to 48.0 (28.7-58.8) mmol/mol ($P < 0.05$). Blood pressure, liver enzymes, and lipids improved, but not significantly (see Table 1). A significant decrease in weight (mean 111 ± 3 to 101 ± 2 kg, $P < 0.05$) was established. BMI and waist circumference decreased significantly, from 34.9 ± 1.2 to 31.1 ± 0.8 ($P < 0.05$) and from 123.2 ± 3.3 to 100.7 ± 2.5 ($P < 0.05$), respectively. There were no differences in trough levels and AUC_{0-3h} of tacrolimus before and after start of semaglutide. One patient suffered from nausea the day following injection, this could be ameliorated by temporally reducing the dosage.

In this small observational study we suggest that GLP-1RA could be an effective treatment for PTDM. This may be especially the case in patients with tacrolimus, since this, widely used, immunosuppressant induces loss of human beta-cell maturity and beta-cell failure through activation of the BMP/SMAD signaling pathway. Glucagon-like peptide 1 receptor agonists (GLP-1RA) are a relatively new class of injectable drugs used in the treatment of T2DM. (1) GLP-1RAs mimic endogenous GLP-1, stimulating insulin release from the pancreas, suppressing glucagon secretion, slowing gastric emptying and increasing satiety. In addition, GLP-1RA have been demonstrated to have beneficial effects on MASLD/MASH. (2) These agents lack hepatic metabolism and hence have limited drug-drug interactions, but they do slow gastric emptying, potentially impairing immunosuppressant absorption. One case series of five kidney transplant recipients with PTDM reported the safety of liraglutide administered for 21 days, without changes in tacrolimus levels. (3) In another study, similar to the case in T2DM, GLP-1 infusion seems to improve (insulin) or even normalize (glucagon) the underlying pathophysiological defects in renal transplant recipients. (4) Previous studies demonstrated the beneficial inhibiting effects of GLP-1 on these pathways, and GLP-1RA may therefore directly counteract tacrolimus-induced beta-cell dysfunction.

In conclusion, semaglutide seems effective, well-tolerated and safe in the treatment of PTDM in patients following liver transplantation. Therefore, GLP-1RA should be considered in patients with PTDM, especially in those with MASH cirrhosis as transplant indication, since recurrence rates are high. These findings need to be confirmed in larger studies.

Table 1. Baseline characteristics and results following 6 months semaglutide

	T=0	T= 6 months	P-value
Male/Female	7/3	-	-
Age (years)	54 ± 5	-	-
Weight (kg)	111 ± 3	101 ± 2	<0.05
Body Mass Index (kg/m ²)	34.9 ± 1	31.1 ± 1	<0.05
Systolic Blood Pressure (mm Hg)	132 ± 8	124 ± 7	ns
Diastolic Blood Pressure (mm Hg)	81 ± 4	75 ± 4	ns
HbA1c (mmol/mol)	66.1	(32.2-80.2)	<0.05
Total Cholesterol (mmol/L)	5.4 ± 0.3	5.1 ± 0.2	ns
ALT (U/L)	68 ± 8	50 ± 5	ns
AST (U/L)	53 ± 5	46 ± 4	ns
Creatinine (μmol/L)	95 ± 8	100 ± 8	ns
Tacrolimus trough levels (μg/L)	4.2 ± 1	4.4 ± 1	ns
Tacrolimus AUC ₀₋₃ (μg*h/L)	142 ± 15	151 ± 18	ns

Values are means ± SE or median (interquartile range). Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; AUC, Area Under Curve.

References

1. Peláez-Jaramillo MJ, Cárdenas-Mojica AA, Gaete PV, Mendivil CO. Post-liver transplantation diabetes mellitus: a review of relevance and approach to treatment. *Diabetes Ther* 2018;9:521-543
2. Petit JM, Cercueil JP, Loffroy R, Denimal D, Bouillet B, Fourmont C, et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the Lira-NAFLD study. *J Clin Endocrinol Metab* 2017;102:407-415
3. Pinelli NR, Patel A, Salinitri FD. Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series. *Diabetes Care* 2013;36:e171-e172
4. Halden TA, Egeland EJ, Åsberg A, Hartmann A, Midtvedt K, Khiabani HZ, et al. GLP-1 restores altered insulin and glucagon secretion in posttransplantation diabetes. *Diabetes Care* 2016;39:617-624